InvestorsHub Logo
Followers 15
Posts 431
Boards Moderated 0
Alias Born 05/17/2018

Re: None

Saturday, 07/21/2018 9:41:52 PM

Saturday, July 21, 2018 9:41:52 PM

Post# of 111075
I love seeing stuff like this.....

Novartis, just a few months ago, bought out a company named AveXis. AveXis has a single gene therapy in clinical trials right now to help people with SMA (Spinal Muscular Atrophy). They were granted Orphan Drug Status by the FDA. Novartis wanted to get this “first to market” treatment under their company’s umbrella and made them an offer that was accepted.

I’ve never heard of AveXis and honestly, I’ve never heard of Spinal Muscular Atrophy.
When I sit for a minute and read about SMA and then I think about CaverStem for ED and then SpineStem for degenerative back disorders and then AmnioStem for anti aging, Cachexia etc..., and I think about how much bigger our patents seem than a gene therapy for SMA that’s in clinical trials. As well as how many more people we will help with our patents, it really makes me think.

Because Novartis paid $8.7B for a company called AveXis, in order to get a gene therapy treatment that at the time was in human trials and was granted orphan drug status.
$8.7B
Personally, I think we are much more valuable than AveXis, or at least will be.

$8.7B with our O/S is $13.25 pps

We should be able to get past this pps amount imo....if you can stand to watch your account grow into the millions without panic selling...lol.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CELZ News